Please Wait.....
Report
Exanthema Market Report and Forecast 2025-2034
Market Report I 2025-06-20 I 400 Pages I EMR Inc.
The exanthema market size was valued at USD 1390.27 Million in 2024, driven by the increasing incidence of viral and bacterial infections and innovations in diagnostic methods across the 8 major markets. The market size is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034 to achieve a value of USD 2513.35 Million by 2034.
Exanthema Market Overview
Exanthema is commonly triggered by infections, often viral, and can manifest as a response to toxins from the organism, skin damage, or an immune reaction. These rashes, nonspecific in nature, show as spots or blotches that may or may not cause itching. They typically spread widely across the body, often more prominently on the trunk than the limbs. Before the rash appears, patients might experience a range of general symptoms including fever, malaise, headaches, reduced appetite, abdominal pain, irritability, muscle aches, and pains.
The exanthema market growth is driven by the rising incidence of viral and bacterial infections, causing skin rashes and related diseases. The escalating prevalence of infectious diseases like measles, rubella, and chickenpox, is significantly contributing to increased exanthema cases, which is expected to require enhanced attention to provide preventive measures and vaccinations, further propelling the market growth. The market is further driven by improvements in healthcare facilities and infrastructure to provide better diagnosis, treatment, and management of exanthemas, encouraging more people to seek medical care.
Consequently, the market is also witnessing innovations in diagnostic methods such as molecular testing and serological assays, acting as major drivers to further bolster the exanthema market demand. Governments and healthcare organizations are launching interesting initiatives to promote vaccination campaigns, especially for diseases linked to exanthemas are contributing to increased market demand.
Initiatives Aiding the Market Growth
The market demand is anticipated to experience significant growth due to a combination of factors such as national and international organizations acting and launching initiatives toward the prevention of exanthema in regions. For instance, the IA2030 Measles & Rubella Partnership, a collaborative initiative led by multiple prominent entities in the field of healthcare and immunization including the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccine Alliance, the Bill and Melinda Gates Foundation, UNICEF, and the World Health Organization (WHO). Such initiatives are aligned towards a common goal of spreading awareness regarding exanthema, likely to contribute significantly to the rising exanthema market share.
Surge in Supplies Due to Unforeseen Outbreak
The market is witnessing a surge in demand for increased treatment supplies and drugs due to the emergence of the condition in some regions. For instance, a recent surge in measles cases in Romania including 460 confirmed cases by August 2023 and significant outbreaks in several counties, has escalated the urgency for effective interventions and preventive measures, elevating the demand for relevant treatments and vaccinations. The market growth is expected to witness escalation owing to the sudden surge in the demand for treatment and vaccination in affecting regions.
FDA Approvals to Aid the Market Growth
The exanthema market growth is also driven by new FDA approvals creating a wave of hope for healthcare professionals and patients. For instance, Merck's groundbreaking announcement of the FDA's approval for intramuscular administration of the MMRV family vaccines-M-M-RII, VARIVAX, and ProQuad marks have also collectively marked a pivotal advancement. This alteration from the conventional subcutaneous injection to intramuscular administration broadens the vaccination landscape enhancing convenience and accessibility as well. Such developments signify promising increased demand for the exanthem market in the forecast period.
Exanthema Market Segmentations
"Exanthema Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Bacterial
- Viral
- Others
Market Breakup by Therapy Type
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
Market Breakup by Treatment
- Anti-Pyretic
- Emollients
- Liquids
- Others
Market Breakup by Drugs
- Corticosteroids
- Antiseizure Agents
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
Market Breakup by Region
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- China
Exanthema Market Regional Analysis
Considering the geographical landscape, the United States is leading the regional market. The market is expected to dominate in the forecast period due to factors such as the presence of the largest patient pool for exanthema and also representing the largest market for its treatment.
The latest data by the CDC Centers for Disease Control and Prevention has revealed that more than 3,700 babies were born with syphilis in 2022, which was more than 10 times the number in 2012. The increase in newborn syphilis follows rising syphilis cases among women of reproductive age combined with social and economic factors that create barriers to high-quality prenatal care and ongoing declines in the prevention infrastructure and resources.
The United States has seen a rise in cases of syphilis and congenital syphilis, leading senior leadership at the U.S. Department of Health and Human Services (HHS) to establish the National Syphilis and Congenital Syphilis Syndemic Federal Taskforce. This task force is dedicated to leading a national public health response to address the issue.
Exanthema Market: Competitor Landscape
In February 2023, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies' mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc
- F. Hoffmann-La Roche Ltd
- Mylan N.V.
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Teva Pharmaceutical Industries
- Bristol Myers Squibb Company
- Bayer AG
- Sun Pharmaceutical Industries
- Manus Aktteva Biopharma LLP
- Perrigo Company plc
- Novartis AG
- GSK Plc.
- CIRON Drugs & Pharmaceuticals Pvt. Ltd.
- Concord Laboratories
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Exanthema Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Exanthema Epidemiology Analysis - 8 Major Markets
5.1 8MM Epidemiology Scenario Overview (2018-2034)
5.2 United States Exanthema Epidemiology Forecast (2018-2034)
5.3 EU-4 and United Kingdom Exanthema Epidemiology Forecast (2018-2034)
5.3.1 Germany Exanthema Epidemiology Forecast (2018-2034)
5.3.2 France Exanthema Epidemiology Forecast (2018-2034)
5.3.3 Italy Exanthema Epidemiology Forecast (2018-2034)
5.3.4 Spain Exanthema Epidemiology Forecast (2018-2034)
5.3.5 United Kingdom Exanthema Epidemiology Forecast (2018-2034)
5.4 Japan Exanthema Epidemiology Forecast (2018-2034)
5.5 China Exanthema Epidemiology Forecast (2018-2034)
6 Exanthema Market Overview - 8 Major Markets
6.1 Exanthema Market Historical Value (2018-2024)
6.2 Exanthema Market Forecast Value (2025-2034)
7 Exanthema Market Landscape - 8 Major Markets
7.1 Exanthema Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Exanthema Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Therapy Type
7.2.3 Analysis by Treatment
7.2.4 Analysis by Drugs
7.2.5 Analysis by Route of Administration
7.2.6 Analysis by Distribution Channel
8 Exanthema Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Exanthema Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter's Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Exanthema Market Segmentation - 8 Major Markets
11.1 Exanthema Market by Disease Type
11.1.1 Market Overview
11.1.2 Bacterial
11.1.3 Viral
11.1.4 Others
11.2 Exanthema Market by Therapy Type
11.2.1 Market Overview
11.2.2 Chemotherapy
11.2.3 Radiation Therapy
11.2.4 Targeted Therapy
11.3 Exanthema Market by Treatment
11.3.1 Market Overview
11.3.2 Anti-Pyretic
11.3.3 Emollients
11.3.4 Liquids
11.3.5 Others
11.4 Exanthema Market by Drugs
11.4.1 Market Overview
11.4.2 Corticosteroids
11.4.3 Antiseizure Agents
11.4.4 Others
11.5 Exanthema Market by Route of Administration
11.5.1 Market Overview
11.5.2 Oral
11.5.3 Parenteral
11.5.4 Others
11.6 Exanthema Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.7 Exanthema Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
11.7.5 China
12 United States Exanthema Market
12.1 United States Exanthema Market Historical Value (2018-2024)
12.2 United States Exanthema Market Forecast Value (2025-2034)
12.3 United States Exanthema Market by Disease Type
12.3.1 Market Overview
12.3.2 Bacterial
12.3.3 Viral
12.3.4 Others
12.4 United States Exanthema Market by Therapy Type
12.4.1 Market Overview
12.4.2 Chemotherapy
12.4.3 Radiation Therapy
12.4.4 Targeted Therapy
13 EU-4 and United Kingdom Exanthema Market
13.1 EU-4 and United Kingdom Exanthema Market Historical Value (2018-2024)
13.2 EU-4 and United Kingdom Exanthema Market Forecast Value (2025-2034)
13.3 EU-4 and United Kingdom Exanthema Market by Disease Type
13.3.1 Market Overview
13.3.2 Bacterial
13.3.3 Viral
13.3.4 Others
13.4 EU-4 and United Kingdom Exanthema Market by Therapy Type
13.4.1 Market Overview
13.4.2 Chemotherapy
13.4.3 Radiation Therapy
13.4.4 Targeted Therapy
14 Japan Exanthema Market
14.1 Japan Exanthema Market Historical Value (2018-2024)
14.2 Japan Exanthema Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Exanthema Market by Disease Type
14.3.1 Market Overview
14.3.2 Bacterial
14.3.3 Viral
14.3.4 Others
14.4 EU-4 and United Kingdom Exanthema Market by Therapy Type
14.4.1 Market Overview
14.4.2 Chemotherapy
14.4.3 Radiation Therapy
14.4.4 Targeted Therapy
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Pfizer Inc
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 F. Hoffmann-La Roche Ltd
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Mylan N.V.
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Fresenius Kabi AG
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Hikma Pharmaceuticals PLC
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Teva Pharmaceutical Industries
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Bristol Myers Squibb Company
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Bayer AG
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Sun Pharmaceutical Industries
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Manus Aktteva Biopharma LLP
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Perrigo Company plc
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Novartis AG
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 GSK Plc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 CIRON Drugs & Pharmaceuticals Pvt. Ltd.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Concord Laboratories
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Exanthema Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security